3D Carbon Nanotube Sponge for Circulating Tumor Cells Detection
Technology
Circulating tumor cells (CTCs) pose a significant challenge in both diagnosing and treating cancer. These cells, originating from primary tumors and traveling through the bloodstream, play a pivotal role in the spread of cancer to distant organs, a process known as metastasis. Early detection and capture of CTCs are essential for effective treatment and prognosis. There’s an urgent need for a more efficient, cost-effective, and accessible approach to CTC detection, as current methods often rely on complex and expensive reagents, limiting their practical use in clinical settings. Researchers at the University of Delaware have developed a method for detecting and capturing CTCs from the bloodstream, utilizing a novel 3D carbon nanotube (CNT) sponge. The sponge exploits the adhesive characteristics of CTCs, trapping them in the CNT network. This fastens and simplifies the process by eliminating the requirement for additional biomarkers or chemicals, making it versatile for capturing various cell types. The 3D CNT sponge exhibits remarkable sensitivity, capturing CTCs within a short 15-minute timeframe without inducing damage, while its fabrication process remains straightforward and cost-effective compared to alternatives such as microfluidic systems. Importantly, this technology fulfills the critical need for early detection and characterization of CTCs, providing vital information for cancer diagnosis and treatment decisions.
Benefits
- Enables the detection of CTCs in the bloodstream, allowing for early detection of metastasis, crucial for improving survival rates.
- Validated for its efficiency, stability, and specificity in capturing CTCs within as little as 15 minutes without damaging cells, providing a rapid and reliable method for diagnosis.
- The fabrication process of the CNT sponge system is straightforward and cost-effective, making it accessible for wide range of clinical applications.
- Offers a marker-free strategy for capturing heterogeneous types of CTCs based on their phenotypes, simplifying the operational complexity in clinical settings.
- High sensitivity and efficiency in capturing cancer cells, up to 70-80% within 30 minutes, outperforming traditional tools and methods.
Applications
- Biotechnology and Pharmaceutical Companies
- Medical Device Manufacturers
- Diagnostic Laboratories
- Research Institutions and Universities
- Healthcare Providers and Clinics